



- | | |
|---|--|
| <p>(51) International Patent Classification:
<i>C07K 16/28</i> (2006.01) <i>A61K 39/395</i> (2006.01)
<i>C12N 15/864</i> (2006.01) <i>A61P 21/02</i> (2006.01)</p> | <p>(74) Agent: LACAVA, Richard et al.; ARENTFOX SCHIFF, LLP, 1717 K Street, NW, WASHINGTON, District of Columbia 20006-5344 (US).</p> |
| <p>(21) International Application Number:
PCT/US2024/048471</p> | <p>(81) Designated States (<i>unless otherwise indicated, for every kind of national protection available</i>): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.</p> |
| <p>(22) International Filing Date:
25 September 2024 (25.09.2024)</p> | |
| <p>(25) Filing Language: English</p> | |
| <p>(26) Publication Language: English</p> | |
| <p>(30) Priority Data:
63/585,198 25 September 2023 (25.09.2023) US
63/671,695 15 July 2024 (15.07.2024) US</p> | |
| <p>(71) Applicant: OYSTER POINT PHARMA, INC. [US/US];
202 Carnegie Center, Suite 106, Princeton, New Jersey 08540 (US).</p> | <p>(84) Designated States (<i>unless otherwise indicated, for every kind of regional protection available</i>): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,</p> |
| <p>(72) Inventor: CARLSON, Eric C.; c/o Oyster Point Pharma, Inc., 202 Carnegie Center, Suite 106, Princeton, New Jersey 08540 (US).</p> | |

(54) Title: INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF1R) ANTIBODIES AND RELATED METHODS OF TREATMENT




FIG. 1

(57) Abstract: Provided herein are antibodies and antigen-binding fragments thereof configured to specifically bind to Insulin-like Growth Factor-1 ("IGF1R"). Nucleic acid molecules encoding the same, pharmaceutical compositions, and methods of treatment based on administration or expression of the anti-IGF1R antibodies and antigen-binding fragments described herein, are also provided.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*